Skip to main content
SpringerLink
Log in

Treatment of Multiple Sclerosis with Interferons

  • Chapter
Treatment of Multiple Sclerosis

Part of the book series: Clinical Medicine and the Nervous System ((CLIN.MED.NERV.))

Abstract

Interferons (IFNs) are a heterogeneous family of naturally occurring glycoproteins first clearly described by Issacs and Lindenmann in 1957 for their capability of blocking or interfering with virus replication and protecting cells against a wide range of viruses (Isaacs and Lindenmann 1957). In addition to their ability to establish an antiviral state in cells, the IFNs activate specific intracellular enzymes, inhibit cell growth, modulate immune responses, activate macrophages, enhance lymphocyte cytotoxicity, and exhibit hormone-like activity (Borden and Ball 1981; Fleischmann et al. 1988; Borden et al. 1982). The mechanisms by which IFNs exert their biological effects are not completely understood. The antiviral, antiproliferative and other biologic effects of IFNs appear to be mediated by de-novo synthesis of a family of proteins.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abreu SL (1982) Suppression of experimental allergic encephalomyelitis by interferon. Immunol Invest 11: 1–7

    Article  CAS  Google Scholar 

  • Abreu SL, Tondreau J, Levine S et al. (1983) Inhibition of passive localized allergic encephalomyelitis by interferon. Int Arch Allergy Appl Immunol 72: 30–33

    Article  PubMed  CAS  Google Scholar 

  • Antel JP, Arnason BGW, Medof ME (1979) Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann Neurol 5: 476–482

    Article  Google Scholar 

  • Antel JP, Bania M, Noronha A et al. (1986) Defective suppressor cell function mediated by T8 cell lines from patients with progressive multiple sclerosis. J Immunol 137: 3436–3439

    PubMed  CAS  Google Scholar 

  • Austims Research Group (1989) Interferon and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo controlled trial. J Neurol Neurosurg Psychiat 52: 566–574

    Article  Google Scholar 

  • Barna BP, Chou SM, Jacobs B et al. (1989) Interferon-B impairs induction of HLA-DR antigen expression in cultured human astrocytes. J Neuroimmunol 23: 45–53

    Article  PubMed  CAS  Google Scholar 

  • Baumhefner RW, Tourtellotte WW, Syndulkok et al. (1987) Effect of intravenous natural beta-interferon on clinical neurofunction, magnetic resonance imaging plaque burden, intrabloodbrain barrier IgG synthesis, blood and cerebrospinal fluid cellular immunology and visual evoked responses. Ann Neurol 22: 171

    Google Scholar 

  • Borden EC, Ball LA (1981) Interferons: Biochemical, cell growth inhibitory and immunological effects. In: EB Brown (ed), Progress in hematology, vol III. Grune & Stratton Inc, New York, pp 299–339

    Google Scholar 

  • Borden EC, Edwards BS, Hawkins MJ, Merritt JA (1982) Interferons: Biological response modification and pharmacology. In: Mihich E (ed), Biological responses in cancer: progress toward potential applications, vol 1. Plenum Publishing, New York, pp 169–218

    Google Scholar 

  • Bornstein MB, Miller A, Slagle S et al. (1987) A pilot trial of COP 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 317: 408–414

    Article  PubMed  CAS  Google Scholar 

  • Camenga DL, Johnson KP, Alter M et al. (1986) Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis. Arch Neurol 43: 1239–1246

    PubMed  CAS  Google Scholar 

  • Confavreux C, Chapuis-Cellier C, Arnaud P et al. (1986) Oligoclonal “fingerprint” of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon. J Neurol Neurosurg Psychiatry 49: 1308–1312

    Article  PubMed  CAS  Google Scholar 

  • Cook D, Dowling PC (1980) Multiple sclerosis and viruses: An overview. Neurology 20: 80–91

    Google Scholar 

  • DeClercq E, Edy VG, de Vlieger H et al. (1975) Intrathecal adminstration of interferon in neonatal herpes. J Pediatr 86: 736–739

    Article  CAS  Google Scholar 

  • Dunnick JK, Galasso GJ (1979) Clinical trials with exogenous interferon: Summary of a meeting. J Infect Dis 139: 109–123

    Google Scholar 

  • Emodi G, Just M, Hernandez R et al. (1975) Circulating interferon in man after administration of exogenous human leukocyte interferon. J Natl Cancer Inst 54: 1045–1049

    PubMed  CAS  Google Scholar 

  • Fleischmann WR, Ramamurthy V, Stanton JG, Baron S (1988) Interferon: mode of action and clinical applications. In: RA Smith (ed), Interferon treatment of neurologic disorders. Marcel Dekker, New York, pp 1–42

    Google Scholar 

  • Fog T (1980) Interferon treatment of multiple sclerosis patients: A pilot study. In: Boese A (ed). Search for the cause of multiple sclerosis and other chronic diseases of the nervous system. Verlag Chemie, Weinheim, pp 491–493

    Google Scholar 

  • Goodkin DE, Rudick RA, Hertsgarrd D (1988) Exacerbation rate and adherence to disease type in a prospectively followed MS population: Implications for clinical trials. Arch Neurol 46: 1107–1112

    Google Scholar 

  • Habif DV, Liptin R, Cantell K (1975) Interferon crosses the blood-cerebrospinal fluid barrier in monkeys. Proc Soc Exp Biol Med 149: 287–298

    PubMed  CAS  Google Scholar 

  • Harfast B, Huddlestone JR, Casali P et al. (1991) Interferon acts directly on human B-lymphocytes to modulate immunoglobulin synthesis. J Immunol 127: 2146–2150

    Google Scholar 

  • Hertz F, Deghenghi R (1985) Effect of rat and beta human interferon on hyperactute experimental allergic encephalomyelitis in rats. Agents Actions 16: 397–403

    Article  PubMed  CAS  Google Scholar 

  • Hilfenhaus J, Weinman E, Major M et al. (1977) Administration of human interferon to rabies virus-infected monkeys affer exposure. J Infect Dis 135: 846–849

    Article  PubMed  CAS  Google Scholar 

  • Hovanessian AG, Marcovistz R, Rivere Y et al. (1988) Production and action of interferon in rabies virus infection. In: Smith RA (ed), Interferon treatment of neurologic disorders. Marcel Dekker, New York, pp 157–186

    Google Scholar 

  • Huber M, Bamborschke S, Assheuer J, Heib WD (1988) Intravenous natural beta interferon treatment of chronic exacerbating-remitting multiple sclerosis: clinical response and MRI/CSF findings. J Neurol 235: 171–173

    Article  PubMed  CAS  Google Scholar 

  • Isaacs A, Lindenmann J (1957) Virus interference. I. The Interferon. Proc R Soc Lond (Biol) 147: 258–267

    Google Scholar 

  • Jacobs L, O’Malley J, Freeman A et al. (1981) Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 214: 1026–1028

    Article  PubMed  CAS  Google Scholar 

  • Jacobs L, O’Malley J, Freeman A et al. (1982) Intrathecal interferon in multiple sclerosis. Arch Neurol 39: 609–615

    PubMed  CAS  Google Scholar 

  • Jacobs L, O’Malley JA, Freeman A et al. (1985) Intrathecal interferon in the treatment of multiple sclerosis: Patient follow-up. Arch Neurol 42: 841–847

    CAS  Google Scholar 

  • Jacobs L, Salazar AM, Herndon R et al. (1986) Multicenter double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet 2: 1411–1413

    Article  PubMed  CAS  Google Scholar 

  • Jacobs L, Salazar AM, Herndon R et al. (1987) Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis: results of a multicenter double-blind study. Arch Neurol 44: 589–595

    PubMed  CAS  Google Scholar 

  • Jacobs L, Salazar AM, O’Malley JA (1988a) The use of interferons in the treatment of certain diseases of the central nervous system. In: S Baron (ed), The interferon system, a current review to 1987. Marcel Dekker Inc., New York, pp 241–264

    Google Scholar 

  • Jacobs L, Salazar A, Herndon RM et al. (1988b) Intrathecal interferon in the treatment of multiple sclerosis. In: Smith RA (ed), Interferon treatment of neurologic disorders. Marcel Dekker, New York, pp 241–262

    Google Scholar 

  • Johnson KP, Knobler RL, Greenstein JI et al. (1990) Recombinant human beta interferon treatment of relapsing-remitting multiple sclerosis. Neurology 40 (Suppl 1): 261

    Google Scholar 

  • Kabat EA, Moore OH, Landow H (1942) An electrophoretic study of the protein components in the cerebrospinal fluid and their relationship to the serum proteins. J Clin Invest 21: 571–577

    Article  PubMed  CAS  Google Scholar 

  • Kaskrukoff LF, Oger JJ, Hashimoto SA et al. (1990) Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology 40: 479–486

    Google Scholar 

  • Knobler RL, Panitch HS, Braheny SL et al. (1984) Systemic alpha interferon therapy in multiple sclerosis. Neurology 34: 1273–1279

    PubMed  CAS  Google Scholar 

  • Leibowitz S (1983) The immunology of multiple sclerosis. In: Hallpike JF, Adams CWM, Tourtellotte WW (eds)’, Multiple sclerosis. Williams and Wilkins, Baltimore, pp 379–412

    Google Scholar 

  • Merrill JE, Targan SR (1988) The immunologic basis for the use of interferons. In: Smith RA (ed), Interferon treatment of neurologic disorders. Marcel Dekker, New York, pp 65–101

    Google Scholar 

  • Misset JL, Mathe G, Horoszewica JS (1981) Intrathecal interferon in meningeal leukemia. N Eng J Med 304: 1544

    Article  CAS  Google Scholar 

  • Montezuma-de-Carallo MJ (1983) A treatment for the chronic disabilities of stable multiple sclerosis. Acta Medicotechnica 31: 155–160

    Google Scholar 

  • Mora JS, Munsat TL, Kao KP et al. (1986) Intrathecal administration of natural human interferon alpha in amyotrophic lateral sclerosis. Neurology 36: 1137–1140

    PubMed  CAS  Google Scholar 

  • Morimoto C, Hailer DA, Weiner HL (1988) Selective loss of suppressor inducer T cell subset in progressive multiple sclerosis: analysis with anti-2H4 monoclonal antibody. N Engl J Med 316: 67–72

    Article  Google Scholar 

  • Neighbor PA (1984) Studies of interferon production and natural killing by lymphocytes from multiple sclerosis patients. Ann NY Acad Sci 436: 181–191

    Article  Google Scholar 

  • Neighbor PA, Miller AE, Bloom BR (1981) Interferon responses of leukocytes in multiple sclerosis. Neurology 31: 561–566

    Google Scholar 

  • Noronha A, Toscas A, Jensen MA (1990) Interferon beta augments suppressor cell function in multiple scelerosis. Ann Neurol 27: 207–210

    Article  PubMed  CAS  Google Scholar 

  • Obbens EAMT, Feum LG, Leavens ME et al. (1984) Interferon in the treatment of intracranial malignancies: A pilot study. Neurology 34 (Suppl 1): 232

    Google Scholar 

  • Panitch HS (1987) Systemic alpha-interferon in multiple sclerosis: long-term patient follow-up. Arch Neurol 44: 61–63

    PubMed  CAS  Google Scholar 

  • Panitch HS (1988) Treatment of subacute sclerosing panencephalitis with interferon. In: Smith RA (ed), Interferon in the treatment of neurologic disorders. Marcel Dekker, New York, pp 187–208

    Google Scholar 

  • Panitch HS, Johnson KP (1988) Treatment of multiple sclerosis by systemic administration of interferon, In Smith RA (ed), Interferon treatment of neurologic disorders. Marcel Dekker, New York, pp 209–232

    Google Scholar 

  • Panitch HS, Heracl RL, Schindler J, Johnson KP (1987) Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 37: 1097–1120

    PubMed  CAS  Google Scholar 

  • Paty DW, Kastrukoff L, Morgan N et al. (1983) Suppressor T-lymphocytes in multiple sclerosis: Analysis of patients with acute relapsing and chronic progressive disease. Ann Neurol 14: 445–449

    Google Scholar 

  • Prange H, Wismann H (1981) Intrathecal use of interferon in encephalitis. N Engl J Med 305: 1283–1284

    Article  PubMed  CAS  Google Scholar 

  • Rose LM, Ginsberg AH, Rothstein TI et al. (1985) Selective loss of a subset of T helper cells in active multiple sclerosis. Proc Natl Acad Sci USA 82: 7389–7393

    Article  PubMed  CAS  Google Scholar 

  • Rudick RA, Jacobs L, Reese PA et al. (1987) Changes in the humoral immune response accompanying intrathecal natural human fibroblast interferon in patients with multiple sclerosis. Neurology 37 (Suppl 1): 305

    Google Scholar 

  • Salazar AM, Gibbs CJ, Gajudsek DC et al. (1983) Clinical use of interferons: Central nervous system disorders. In: Came P, Carter WA (eds), Handbook of Experimental Pharmacology: vol 71. Springer-Verlag, New York, pp 472–497

    Google Scholar 

  • Schnaper HW, Aune TM, Pierce CW (1983) Suppressor T cell activation by human leukocyte interferon. J Immunol 131: 2301–2306

    PubMed  CAS  Google Scholar 

  • Slatkin NE, Jaeckle KA, Lukes SA et al. (1984) Treatment of leptomeningeal gliomatosis with human leukocyte interferon: Results in two patients. Neurology 34 (Suppl 1): 151

    Google Scholar 

  • Smith RA, Norris F, Palmer D et al. (1985) Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clin Pharmacol Ther 1: 85–88

    Article  Google Scholar 

  • Smith RA, Landel CP, Cornelius CE, Revel M (1987) Mapping the action of interferon on primate brain. In: Cantell K, Schellekens H (eds), The biology of the interferon system. Martinus Nijhoff, Boston, pp 563–566

    Google Scholar 

  • Stewart WE II (1979) The interferon system. Springer-Verlag, New York

    Google Scholar 

  • Ter Meulen V, Stephenson JR (1983) The possible role of viral infections in multiple sclerosis and other related demyelinating diseases. In: Hallpike JF, Adams CWM, Tourtellotte WW (eds), Multiple sclerosis. Williams and Wilkins, Baltimore, pp 241–274

    Google Scholar 

  • Tourtellotte WW, Walsh MJ, Baumhefner RW et al. (1984) The current status of multiple sclerosis intra-blood-brain barrier IgG synthesis. Ann NY Acad Sci 436: 52–67

    Article  PubMed  CAS  Google Scholar 

  • Ververken D, Carton H, Billiau A et al. (1979) Intrathecal administration of interferon in MS patients. In: Karcher D, Lowenthal A, Strosberg AD (eds), Humoral immunity in neurological disease. Plenum, New York, pp 625–627

    Google Scholar 

  • Vervliet G, Claeys H, Van Haver H et al. (1983) Interferon production and natural killer cell (NK) activity in leukocyte cultures from multiple sclerosis patients. J Neurol Sci 60: 137–150

    CAS  Google Scholar 

  • Wills R, Smith RA (1988) Pharmacokinetics of interferons, In: Smith RA (ed) Interferon treatment of neurologic disorders. Marcel Dekker, New York, pp 103–134

    Google Scholar 

Download references

Authors
  1. Lawrence Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frederick Munschauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195-5244, Cleveland, OH, USA

    Richard A. Rudick MD  & Donald E. Goodkin MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag London Limited

About this chapter

Cite this chapter

Jacobs, L., Munschauer, F. (1992). Treatment of Multiple Sclerosis with Interferons. In: Rudick, R.A., Goodkin, D.E. (eds) Treatment of Multiple Sclerosis. Clinical Medicine and the Nervous System. Springer, London. https://doi.org/10.1007/978-1-4471-3184-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-3184-7_11

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-3186-1

  • Online ISBN: 978-1-4471-3184-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation